Bicocca Open Archive

Logo unimib boa
SENNI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 21.513
NA - Nord America 15.034
EU - Europa 8.786
SA - Sud America 3.200
AF - Africa 452
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 11
Totale 49.033
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.446
SG - Singapore 7.169
VN - Vietnam 4.981
HK - Hong Kong 3.984
CN - Cina 2.887
BR - Brasile 2.436
RU - Federazione Russa 2.318
IT - Italia 1.591
IE - Irlanda 1.343
DE - Germania 910
SE - Svezia 608
FR - Francia 565
IN - India 451
AR - Argentina 325
CA - Canada 317
GB - Regno Unito 306
BD - Bangladesh 274
FI - Finlandia 254
ID - Indonesia 243
KR - Corea 235
IQ - Iraq 188
MX - Messico 177
JP - Giappone 154
UA - Ucraina 150
AT - Austria 142
TR - Turchia 133
NL - Olanda 127
ZA - Sudafrica 119
EC - Ecuador 118
PK - Pakistan 117
SA - Arabia Saudita 94
ES - Italia 91
PH - Filippine 89
CO - Colombia 86
PL - Polonia 77
VE - Venezuela 66
MY - Malesia 61
UZ - Uzbekistan 59
MA - Marocco 58
TN - Tunisia 56
PY - Paraguay 54
BE - Belgio 47
CL - Cile 45
TH - Thailandia 43
JO - Giordania 41
EG - Egitto 38
AE - Emirati Arabi Uniti 37
KE - Kenya 35
ET - Etiopia 34
AU - Australia 29
UY - Uruguay 29
RO - Romania 28
DK - Danimarca 27
DZ - Algeria 26
NP - Nepal 26
IR - Iran 25
KZ - Kazakistan 25
PE - Perù 25
HU - Ungheria 22
PS - Palestinian Territory 22
CR - Costa Rica 21
LB - Libano 21
CZ - Repubblica Ceca 20
LT - Lituania 20
OM - Oman 19
IL - Israele 18
PT - Portogallo 18
CH - Svizzera 17
NO - Norvegia 17
AZ - Azerbaigian 16
TW - Taiwan 16
RS - Serbia 15
NG - Nigeria 13
SY - Repubblica araba siriana 13
BO - Bolivia 12
JM - Giamaica 12
KG - Kirghizistan 11
AO - Angola 10
CI - Costa d'Avorio 10
QA - Qatar 10
SN - Senegal 10
TT - Trinidad e Tobago 10
GR - Grecia 9
LV - Lettonia 9
NI - Nicaragua 9
PA - Panama 9
AL - Albania 8
DO - Repubblica Dominicana 8
HN - Honduras 8
KW - Kuwait 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
BH - Bahrain 7
BW - Botswana 7
GE - Georgia 7
MD - Moldavia 7
AM - Armenia 6
BG - Bulgaria 6
BY - Bielorussia 6
GA - Gabon 6
Totale 48.928
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.929
Singapore 3.872
Ho Chi Minh City 1.569
San Jose 1.399
Dublin 1.295
Ashburn 1.246
Hanoi 1.222
Chandler 806
Princeton 744
New York 714
Chicago 713
Hefei 602
Ann Arbor 578
The Dalles 562
Frankfurt am Main 557
Los Angeles 485
Lauterbourg 430
Santa Clara 425
Dallas 349
Beijing 343
Lawrence 291
Moscow 289
Fairfield 288
Altamura 268
Milan 222
Seoul 219
São Paulo 214
Buffalo 206
Toronto 197
Helsinki 177
Council Bluffs 175
Da Nang 158
Jakarta 157
Andover 147
Nuremberg 147
Wilmington 145
Haiphong 141
Seattle 129
Shanghai 119
Rome 112
Houston 110
Cambridge 108
San Diego 107
Woodbridge 102
Boardman 97
Tokyo 96
Biên Hòa 92
Ha Long 91
Quận Bình Thạnh 91
Rio de Janeiro 91
Ninh Bình 90
Can Tho 75
Hải Dương 75
London 74
Baghdad 73
Guangzhou 68
Thái Nguyên 68
Vienna 66
Salt Lake City 65
Munich 64
Orem 60
Bắc Ninh 59
Pune 59
Washington 54
Vũng Tàu 53
Bắc Giang 51
Lappeenranta 51
Brasília 50
Mexico City 50
Naples 50
San Mateo 50
Warsaw 50
Tashkent 49
Elk Grove Village 46
Belo Horizonte 45
Johannesburg 45
Atlanta 44
Brooklyn 44
Dhaka 44
Brussels 43
Montreal 43
Phoenix 41
Guayaquil 40
Quận Một 40
Buenos Aires 39
Istanbul 39
Riyadh 38
Amman 35
Curitiba 35
Quito 35
Denver 34
Jeddah 34
Chennai 33
Kent 33
Lahore 33
San Francisco 33
Stockholm 33
Kuala Lumpur 32
Phủ Lý 32
Vinh 32
Totale 29.055
Salva come PNG Salva come JPEG
Nome #
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials 621
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial 548
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 529
Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction between Supine Versus Upright Exercise Hemodynamic Testing 483
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes 482
Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction 463
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: Results from an Italian multicenter study 449
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 437
Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study 428
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry 403
A matter of sex—persistent predictive value of MECKI score prognostic power in men and women with heart failure and reduced ejection fraction: a multicenter study 343
Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years 340
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 338
Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study 332
Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study 292
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials 291
Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study 283
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 283
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients 279
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization 277
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 274
Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study 263
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction 263
Clonal hematopoiesis of indeterminate potential: implications for the cardiologists 259
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial 251
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure 247
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 245
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 228
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 226
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 220
Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation 216
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 210
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 208
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 203
Position paper ANMCO sull'utilizzo della terapia con sacubitril/valsartan nel paziente con scompenso cardiaco [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure] 201
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 198
An uncommon and challenging finding regarding the tricuspid valve: Case report, clinical considerations, and practical management 194
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 194
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 188
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 184
QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance 184
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis 183
Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure 183
The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique 182
Right ventricular reserve in cardiopulmonary disease: A simultaneous hemodynamic and three-dimensional echocardiographic study 179
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment 175
Erratum: Heart failure at the crossroads: Moving beyond blaming stakeholders to targeting the heart (Eur J Heart Fail (2015) 17:8 (760-763) doi:10.1002/ejhf.315)) 175
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 173
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus 163
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease 161
Emergency surgery of acute coronary insufficiency [La chirurgia d'urgenza nell'insufficienza coronarica acuta.] 159
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici] 158
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry 158
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities 157
Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects 157
The chronic heart failure evolutions: Different fates and routes 157
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF 155
Exercise Right Ventricular-Pulmonary Arterial Coupling and Functional Outcome in Patients Undergoing Surgery for Secondary Ischemic Mitral Regurgitation 152
A 57-year-old man with rapidly progressive pulmonary hypertension 148
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens 146
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), with the special contribution of the Heart Failure Association (HFA) of the ESC 142
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 141
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19 141
S Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction 140
Vasopressors and inotropes in cardiogenic shock: Is there room for "adrenaline resuscitation"? 140
The follow-up of patients undergoing percutaneous coronary intervention: Potential impact of the application of a clinical pathway-structured management on the hospital-community integration and modulated on the patient's clinical risk 139
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 137
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF 136
The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels 135
Evolocumab and clinical outcomes in patients with cardiovascular disease 135
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial 135
Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study 134
Prognostic Value of sST2 in Heart Failure 133
Heart failure with preserved ejection fraction: Update on diagnosis and therapy [Scompenso cardiaco con frazione di eiezione preservata: Update in tema di diagnosi e terapia] 133
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 132
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review 131
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF 130
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction 128
Bacterial Pericarditis due to Providencia stuartii An Atypical Case of Relapsing Pericarditis 127
Tailored approach to trans-catheter palliation of critically reduced pulmonary blood supply. Data on long term follow up 126
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 125
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC 125
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry 124
Incidental cardiac aspergillomas in an immunocompromised woman 123
Assistenza ventricolare sinistra dopo correzione combinata di stenosi valvolare aortica e coartazione istmica 123
An unusual case of cardiac aspergillosis 122
Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial 120
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 120
Trattamento conservativo della valvola mitrale in presenza di endocardite infettiva 119
Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy 119
Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation 119
Acute necrotizing eosinophilic myocarditis presenting with cardiogenic shock after mRNA booster dose for COVID-19: Case report and review of literature 118
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial 118
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial 118
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug 118
Sex-related differences in patients with coronavirus disease 2019: Results of the Cardio-COVID-Italy multicentre study 116
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis 116
TAVI in moderate aortic stenosis and heart failure: pros and cons 116
Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol 115
Low dosage of cyclosporine and increased occurrence of chronic rejection in heart-transplanted patients 114
Totale 20.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.489
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.489
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021184 0 0 0 0 0 0 0 0 0 0 81 103
2021/20222.953 79 76 77 45 88 27 28 49 41 63 1.676 704
2022/20233.988 640 1.090 282 272 208 769 54 195 273 42 95 68
2023/20243.637 68 105 98 138 590 1.004 689 92 333 95 38 387
2024/202512.162 466 1.221 441 471 1.283 473 1.104 347 1.518 1.639 946 2.253
2025/202626.900 4.379 3.430 1.888 2.627 2.724 1.395 3.931 1.451 2.079 2.286 710 0
Totale 50.749